- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilar Articles for the Week of June 21
Here are the top 5 biosimilar articles for the week of June 21, 2021.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilar articles for the week of June 21, 2021.
Number 5: The Supreme Court ruled that plaintiffs had no standing to challenge the constitutionality of the Affordable Care Act, saving the Biologics Price Competition and Innovation Act (BPCIA), which is the regulatory pathway for biosimilar approvals.
Number 4: Sophia Z. Humphreys, PharmD, MHA, explained how biosimilar utilization management can enable health care institutions to put COVID-19–related financial wreckage behind them.
Number 3: Real-world studies demonstrated comparable safety for trastuzumab biosimilars (Kanjinti and Zedora) vs the originator (Herceptin) and were presented at the ASCO 2021 Annual Meeting.
Number 2: Positive findings were reported for use of a bevacizumab biosimilar (Byvasda) in combination with sintilimab as a first-line treatment for patients with advanced hepatocellular carcinoma (HCC).
Number 1: The “winner-takes-all” tender process for biosimilar procurement in the European Union runs the risk of driving competitors out of the market, authors of a new survey contended.
To read all of these articles and more, visit centerforbiosimilars.com.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Sustainable Biosimilar Markets Achieve Widespread Market Uptake Through Collective Action
April 22nd 2024Despite current challenges in biosimilar market growth due to stakeholder disagreements, a recent commentary proposes that applying collective action theory can achieve widespread biosimilar market uptake by fostering collaboration for long-term benefits.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
